



#9  
EWS  
66976  
1696

ATTORNEY'S DOCKET NO: B0801/7202 (AWS)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Weiner et al.  
Serial No: 09/809,745  
Conf. No.: 5345  
Filed: March 15, 2001  
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL  
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES

Examiner: Unknown  
Art Unit: 1646

RECEIVED  
MAY 24 2002  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 20<sup>th</sup> day of May, 2002.

  
Yvonne Lingo

Commissioner for Patents  
Washington, D.C. 20231

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ Form PTO-1449 with References Cited
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

If a fee is determined to be required, please charge the fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,  
*Weiner et al., Applicants*

By:   
Alan W. Steele, Reg. No. 45,128  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Telephone (617) 720-3500

Docket No. B0801/7202 (AWS)  
Dated: May 20, 2002



ATTORNEY'S DOCKET NO: B0801/7202 (AWS)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Weiner et al.  
Serial No: 09/809,745  
Conf. No.: 5345  
Filed: March 15, 2001  
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL  
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES  
  
Examiner: Unknown  
Art Unit: 1646

RECEIVED  
MAY 24 2002  
TECH CENTER 1600/2300

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 26<sup>th</sup> day of May, 2002.

  
Yvonne Lingo

---

Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

**PART II: Information Cited**

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.



Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,  
*Weiner et al., Applicants*

By:   
\_\_\_\_\_  
Alan W. Steele, Reg. No. 45,128  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Telephone (617) 720-3500

Docket No. B0801/7202 (AWS)  
Dated: May 20, 2002  
X

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/809,745	ATTY. DOCKET NO.: B0801/7202	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 		FILING DATE: March 15, 2001		
		APPLICANT: Weiner et al.		
		GROUP ART UNIT: 1646		EXAMINER: [Signature]
Sheet 1	of 1			

#### U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B14	WIPO	WO95/25744	A1	Rijksuniversiteit Utrecht	09-28-1995	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C41	CHEN W et al., Human 60-kDa heat-shock protein: a danger signal to the innate immune system. <i>J Immunol.</i> 1999 Mar 15;162(6):3212-9.	
	C42	FRANCIS JN et al., The route of administration of an immunodominant peptide derived from heat-shock protein 65 dramatically affects disease outcome in pristane-induced arthritis. <i>Immunology.</i> 2000 Mar;99(3):338-44.	
	C43	HAQUE MA et al., Suppression of adjuvant arthritis in rats by induction of oral tolerance to mycobacterial 65-kDa heat shock protein. <i>Eur J Immunol.</i> 1996 Nov;26(11):2650-6.	
	C44	PRAKKEN BJ et al., Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. <i>Proc Natl Acad Sci U S A.</i> 1997 Apr 1;94(7):3284-9.	
	C45	THOMPSON SJ et al., An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. <i>J Immunol.</i> 1998 May 1;160(9):4628-34.	
	C46	VAN DER ZEE R et al., T cell responses to conserved bacterial heat-shock-protein epitopes induce resistance in experimental autoimmunity. <i>Semin Immunol.</i> 1998 Feb;10(1):35-41.	
	C47	VAN EDEN W et al., Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response. <i>Immunol Rev.</i> 1998 Aug;164:169-74	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]